首页> 外文期刊>Circulation journal >Biochemical and Physiological Regulation of Cardiac Myocyte Contraction by Cardiac-Specific Myosin Light Chain Kinase
【24h】

Biochemical and Physiological Regulation of Cardiac Myocyte Contraction by Cardiac-Specific Myosin Light Chain Kinase

机译:心肌特异性肌球蛋白轻链激酶对心肌细胞收缩的生化和生理调节

获取原文
           

摘要

Cardiac-specific myosin light chain kinase (cMLCK) is the kinase predominantly responsible for the maintenance of the basal level of phosphorylation of cardiac myosin light chain 2 (MLC2), which it phosphorylates at Ser-15. This phosphorylation repels the myosin heads from the thick myosin filament and moves them toward the thin actin filament. Unlike smooth muscle cells, MLC2 phosphorylation in striated muscle cells appears to be a positive modulator of Ca2+ sensitivity that shifts the Ca2+-force relationship toward the left and increases the maximal force response and thus does not initiate muscle contraction. Recent studies have revealed an increasing number of details of the biochemical, physiological, and pathophysiological characteristics of cMLCK. The combination of recent technological advances and the discovery of a novel class of biologically active nonstandard peptides will hopefully translate into the development of drugs for the treatment of heart diseases.??( Circ J ?2013; 77: 2218–2225)
机译:心脏特异性肌球蛋白轻链激酶(cMLCK)是主要负责维持心脏肌球蛋白轻链2(MLC2)磷酸化基础水平的激酶,其在Ser-15处磷酸化。这种磷酸化作用从厚的肌球蛋白细丝排斥了肌球蛋白的头部,并将它们移向细的肌动蛋白丝。与平滑肌细胞不同,横纹肌细胞中的MLC2磷酸化似乎是Ca 2 + 敏感性的正调节剂,使Ca 2 + 力关系向左移动并增加最大的力量反应,因此不会引发肌肉收缩。最近的研究揭示了cMLCK的生化,生理和病理生理特征的细节越来越多。近期技术进步​​与新型生物活性非标准肽的发现相结合,有望转化为治疗心脏病的药物。(Circ J?2013; 77:2218–2225)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号